IPO
Immunicum AB announced the composition of the Nomination Committee on 19 October 2018.
Lonza reported a 9% organic sales, 12% organic CORE EBITDA and 14% organic CORE EBIT growth.
Numerous biotech companies had filed for initial public offerings (IPOs) during the five-week government shutdown, but were unlikely to actually be able to be listed until the U.S. Securities and Exchange Commission (SEC) had a chance to review their filings.
TESARO, Inc. announced that pursuant to the terms of the Indenture and the First Supplemental Indenture to the Indenture governing the terms of its 3.00% Convertible Senior Notes due 2021
San Diego-based Gossamer Bio is pulling the trigger on an initial public offering by harnessing a legal loophole that will allow the company to move forward with its listing plans despite the partial government shutdown, now in its 34th day.
Bellerophon Therapeutics, Inc. today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $0.70 per share
A 2013 study that analyzes IPO withdrawals between 1999 and 2004 found that about 13 percent returned later for a successful IPO, 36 percent turned again to raising capital privately, and 42 percent either merged or were acquired by other companies—another common strategy for biotechs. And about 11 percent filed bankruptcy.
Last year was a record year for biotech initial public offerings (IPOs), but 2019 is off to a slow and rocky start because of the government shutdown, which today is in its 31st day.
Kindred Biosciences, Inc. today announced the pricing of an underwritten public offering of 4,215,000 shares of its common stock at a public offering price of $9.50 per share
Mirati Therapeutics, Inc. (Nasdaq: MRTX) announced the pricing of an underwritten public offering of 1,612,903 shares of its common stock at a price to the public of $62.00 per share.
PRESS RELEASES